Nanopharm And Fluidda Join Forces To Speed Up Inhaled Drug Approvals
Their Modelling Technologies Promise To Accelerate USFDA Approvals For Inhaled Generics
Nanopharm and Fluidda are collaborating on a computational approach for assessing bioequivalence in inhaled generics. Their project aims to ease the USFDA approvals process for a drug class whose pharmacokinetic properties are notoriously difficult to observe.
